AROC AroCell AB

AroCell expands its distribution network and signs distribution agreement with Inveniolife

AroCell expands its distribution network and signs distribution agreement with Inveniolife

AroCell AB (publ) announce today that a distribution agreement has been signed with the Mumbai based company Inveniolife Technology Pvt. Ltd. for the promotion and distribution of the AroCell TK 210™ ELISA in India.

AroCell’s TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information about cell proliferation and disruption in patients with cancer tumors. TK 210 ELISA may also support clinicians to optimize treatment and estimate the risk of recurrence.

“We are looking forward to this new collaboration with Inveniolife for the distribution and promotion of AroCell TK 210 ELISA in India”, says Michael Brobjer, AroCell’s CEO. “This is in line with our strategy to reach all major markets with our product by collaboration with top line distributors. Inventiolife is a well established distributor for the drug discovery, pharma and clinical market in India and has a strong sales team covering academic institutions, CROs and drug discovery companies throughout India.”

This agreement supports AroCell´s commercialization strategy to make AroCell TK 210 ELISA widely available and to facilitate the use of the product in clinical research, routine clinical laboratories as well as for drug development within the pharmaceutical industry.

For more information:

Michael Brobjer, CEO

Telephone: +46(0)18 50 30 20

E-mail:

AroCell is obliged to make public this information pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of Michael Brobjer, May 2, 2019 at 08:00.

About AroCell

AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North with Redeye AB as Certified Adviser: , +46 (0)8 121 576 90.

For more information;

 

 

Attachment

EN
02/05/2019

Underlying

AROCAroCell AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AroCell AB

 PRESS RELEASE
Free
AROC AROCELL AB

Thymidine Kinase 1 can be used for early detection of therapy response...

Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based cell-loss metric after two cycles of therapy predicted the status at the operation after six cycles of chemotherapy. The metric predicted early on whether or not the chemotherapy works. The purpose with this PROMIX study is to investigate whether a cell-loss metric, defined as the ratio between s...

September 18, 2019 1 EN
 PRESS RELEASE
Free
AROC AROCELL AB

AroCell expands with a Regulatory Affairs Director

AroCell expands with a Regulatory Affairs Director AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus on the US market and FDA clearance of our TK 210 ELISA. Peter Löwendahl has almost 30 years of experience in quality and regulatory affairs and has previously been responsible for Quality and Regulatory affairs at Elekta AB and global regulatory responsibility for GE Healthcare's Life science division. In the last 3 years, he works mainly as a...

September 11, 2019 1 EN
 PRESS RELEASE
Free
AROC AROCELL AB

AroCell AB (publ) Interim Report January 1st to June 30th 2019

AroCell AB (publ) Interim Report January 1st to June 30th 2019 Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as the given partner and supplier of a reliable method for measuring Thymidine kinase 1 in the blood permeates everything we do. During the quarter, we increased sales, signed more distributor agreements, signed a collaboration agreement with CLIA lab in the US and started a collaboration with the Dana Farber Cancer Institute in the USA...

August 21, 2019 1 EN
 PRESS RELEASE
Free
AROC AROCELL AB

AroCell signs a new distributor agreement in the USA and Canada

AroCell signs a new distributor agreement in the USA and Canada AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United States and Canada. Diapharma sells tests and instrumentation for the diagnostic and research fields and provides strong technical competence and experience to ensure that their customer expectations are met. “We look forward to this new collaboration with Diapharma Group for the distribution and promotion of AroCell TK 210 ELISA in...

August 6, 2019 1 EN
 PRESS RELEASE
Free
AROC AROCELL AB

AroCell enters a collaboration with Dana Farber Cancer Institute

AroCell enters a collaboration with Dana Farber Cancer Institute Today AroCell announces a collaboration with Dana Faber Cancer Institute to evaluate AroCell’s TK 210 ELISA assay on CDK4/6 inhibitor treated patients. The aim of the study is to examine concordance of TK 1 concentration in serum and clinical response on treatment. In the study samples will be collected from patients treated with CDK 4/6 inhibitor palbociclib throughout the course of the treatment and the concordance between AroCell’s TK 210 ELISA assay and clinical response will be evaluated. The study will include about 2...

August 1, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch